Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CYCLOSET

« Back to Dashboard
Cycloset is a drug marketed by Veroscience and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug.

This drug has one hundred and eighteen patent family members in twenty-eight countries.

The generic ingredient in CYCLOSET is bromocriptine mesylate. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.

Summary for Tradename: CYCLOSET

Patents:8
Applicants:1
NDAs:1
Suppliers: see list1

Pharmacology for Tradename: CYCLOSET

Ingredient-typeErgolines
Drug ClassErgot Derivative

Clinical Trials for: CYCLOSET

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Veroscience
CYCLOSET
bromocriptine mesylate
TABLET;ORAL020866-001May 5, 2009RXYes5,716,957<disabled><disabled>
Veroscience
CYCLOSET
bromocriptine mesylate
TABLET;ORAL020866-001May 5, 2009RXYes8,137,994<disabled><disabled>
Veroscience
CYCLOSET
bromocriptine mesylate
TABLET;ORAL020866-001May 5, 2009RXYes8,431,155<disabled>Y<disabled>
Veroscience
CYCLOSET
bromocriptine mesylate
TABLET;ORAL020866-001May 5, 2009RXYes5,679,685<disabled>Y<disabled>
Veroscience
CYCLOSET
bromocriptine mesylate
TABLET;ORAL020866-001May 5, 2009RXYes8,613,947<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: CYCLOSET

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,760,047 Method for treatment of obesity using prolactin modulators and diet<disabled in preview>
5,654,313 Method for modifying or regulating the glucose metabolism of an animal or human subject<disabled in preview>
5,496,803 Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia in vertebrates<disabled in preview>
6,004,972 Therapeutic process for the treatment of the pathologies of type II diabetes<disabled in preview>
5,344,832 Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CYCLOSET

Country Document Number Publication Date
European Patent Office0735863Oct 09, 1996
Canada2194501Jan 25, 1996
European Patent Office0440333Aug 07, 1991
Israel114300Oct 31, 1995
Uruguay34776Nov 29, 2013
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc